The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Ultra-low-dose immunotherapy plus oral metronomic chemotherapy versus paclitaxel-carboplatin in platinum-sensitive recurrent or metastatic head and neck squamous cell carcinoma: A randomized phase III trial.
 
Minit Shah
No Relationships to Disclose
 
Vanita Noronha
Research Funding - AstraZeneca (Inst); Johnson & Johnson/Janssen (Inst); Merck (Inst); Nanobiotix (Inst); Novartis (Inst); Roche India (Inst)
Travel, Accommodations, Expenses - American Society of Clinical Oncology
 
Nandini Menon
No Relationships to Disclose
 
Gaurav Kumar
No Relationships to Disclose
 
Laxman Sahu
No Relationships to Disclose
 
Yashashree Parida
No Relationships to Disclose
 
Prajakta Dhanvijay
No Relationships to Disclose
 
Kamesh Maske
No Relationships to Disclose
 
Srushti Shah
No Relationships to Disclose
 
Kavita Nawale
No Relationships to Disclose
 
Manish Pachpande
No Relationships to Disclose
 
Amit Janu
No Relationships to Disclose
 
Nivedita Chakrabarty
No Relationships to Disclose
 
Neha Mittal
No Relationships to Disclose
 
Munita Bal
No Relationships to Disclose
 
Swapnil Rane
No Relationships to Disclose
 
Asawari Patil
No Relationships to Disclose
 
Kumar Prabash
Research Funding - Alkem Laboratories (Inst); Aurigene Oncology Limited (Inst); BDR Pharmaceutics (Inst); Biocon (Inst); Biorasi Clinical Sci Pvt (Inst); Dr. Reddy's Laboratories (Inst); Fortrea (Inst); Fresenius Kabi (Inst); Hexal Pharmaceuticals (Inst); Johnson and Johnson (Inst); Jubilant Therapeutics (Inst); MSD (Inst); NATCO Pharma (Inst); Novartis (Inst); Roche (Inst); Samsung Bioepis (Inst)